Mylan Inc announced that its subsidiary, Mylan Pharmaceuticals Inc, received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fluoxetine capsules USP, 10 mg and 20 mg.
Fluoxetine capsules, indicated for the treatment of premenstrual dysphoric disorder (PMDD) are the generic version of Eli Lilly's Sarafem Pulvules capsules.
Currently, Mylan has 112 ANDAs pending FDA approval, 23 of which are potential first-to-file opportunities.
Mylan, which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.